Anzeige
Mehr »
Freitag, 03.10.2025 - Börsentäglich über 12.000 News
Starkes Upside-Potenzial: Wachstumsstory mit starken Gehalten und großem Explorationspotenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A419Q2 | ISIN: US71902K4022 | Ticker-Symbol:
NASDAQ
02.10.25 | 21:56
5,400 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CERO THERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
CERO THERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur CERO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.09.CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report1
CERO THERAPEUTICS Aktie jetzt für 0€ handeln
22.09.CERo Therapeutics doses third patient in AML clinical trial1
22.09.CERo Therapeutics Holdings, Inc.: CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort174Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO...
► Artikel lesen
09.09.CERo Therapeutics secures key patent protection for cancer therapy1
09.09.CERo Therapeutics sichert wichtigen US-Patentschutz für Krebstherapie2
09.09.CERo Therapeutics Holdings, Inc.: CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 20411
08.09.CERo Therapeutics administers second dose in AML clinical trial1
08.09.CERo Therapeutics verabreicht zweite Dosis in klinischer AML-Studie2
08.09.CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia74Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLOBE...
► Artikel lesen
05.09.CERo Therapeutics Stock Drops 13% Despite FDA Fast Track For Lead AML Therapy1
05.09.CERo Therapeutics Holdings, Inc.: CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)171Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company's lead cancer immunotherapy program SOUTH SAN FRANSCISCO...
► Artikel lesen
04.09.CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report1
22.08.CERO THERAPEUTICS HOLDINGS, INC. - 10-Q, Quarterly Report1
15.08.CERO THERAPEUTICS HOLDINGS, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB1
31.07.CERo Therapeutics Holdings, Inc.: CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236144Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif....
► Artikel lesen
28.07.CERO THERAPEUTICS HOLDINGS, INC. - S-8, Securities to be offered to employees in employee benefit plans1
21.07.Cero Therapeutics registers up to 12.5M shares for potential sale under equity agreement with Keystone1
21.07.CERO THERAPEUTICS HOLDINGS, INC. - S-1, General form for registration of securities1
18.07.Cero Therapeutics schließt weitere Tranche der Serie-D-Finanzierung ab9
18.07.CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report1
Weiter >>
79 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1